HC Wainwright Cuts Earnings Estimates for Wave Life Sciences

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities researchers at HC Wainwright reduced their FY2025 earnings per share estimates for Wave Life Sciences in a research note issued on Wednesday, March 5th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.87) per share for the year, down from their prior forecast of ($0.74). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Wave Life Sciences’ FY2026 earnings at ($1.07) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.71 EPS.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The company had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million.

Several other analysts also recently issued reports on WVE. Mizuho boosted their target price on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Jefferies Financial Group began coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target on the stock. Truist Financial raised their price objective on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.60.

Wave Life Sciences Stock Performance

Shares of NASDAQ:WVE opened at $9.40 on Friday. The firm has a 50 day simple moving average of $11.44 and a 200 day simple moving average of $11.24. Wave Life Sciences has a 52 week low of $4.25 and a 52 week high of $16.74. The company has a market cap of $1.44 billion, a PE ratio of -8.47 and a beta of -1.04.

Insider Activity at Wave Life Sciences

In related news, CEO Paul Bolno sold 169,025 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. This represents a 33.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 29.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Wave Life Sciences

Institutional investors have recently bought and sold shares of the stock. Maverick Capital Ltd. raised its stake in shares of Wave Life Sciences by 31.0% in the 3rd quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock valued at $82,390,000 after acquiring an additional 2,378,159 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Wave Life Sciences by 63.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company’s stock valued at $63,074,000 after purchasing an additional 1,972,262 shares during the last quarter. Loomis Sayles & Co. L P bought a new position in shares of Wave Life Sciences in the fourth quarter valued at approximately $20,545,000. Polar Capital Holdings Plc acquired a new stake in shares of Wave Life Sciences in the fourth quarter worth $12,370,000. Finally, FMR LLC boosted its holdings in shares of Wave Life Sciences by 174.5% during the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock worth $12,630,000 after buying an additional 979,110 shares during the period. 89.73% of the stock is currently owned by institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.